MYRIAD GENETICS INC (MYGN)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for MYGN
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| MYGN | Chief Scientific Officer | 46 | ["Chief Scientific Officer since April 2022","Interim Chief Scientific Officer at Myriad from January 2022 to April 2022","Senior Vice President, R&D from January 2022 to April 2022","Vice President, Bioinformatics from October 2019 to December 2021","Senior Director, Clinical Development from August 2018 to September 2019","Various positions at Myriad Women's Health from April 2014 to July 2018","Ph.D. in Biophysics from Harvard University","Bachelor of Arts degree in Biochemical Sciences from Harvard University"] | [] | 2026 |
Biography sourced from the proxy statement filing.
Dale Muzzey has served as Chief Scientific Officer since April 2022. Previously, he served at Myriad as Interim Chief Scientific Officer and Senior Vice President, R&D from January 2022 to April 2022; Vice President, Bioinformatics, from October 2019 to December 2021; and Senior Director, Clinical Development from August 2018 to September 2019. From April 2014 to July 2018, Dr. Muzzey also served in a number of positions of increasing responsibility at Myriad Women's Health, including Director, Scientific Affairs, Staff Scientist, Computational Biology, Senior Scientist, and Computational Scientist I. Dr. Muzzey received a Bachelor of Arts degree in Biochemical Sciences and a Ph.D. in Biophysics from Harvard University. Age: 46